memantine and Anxiety Disorders
memantine has been researched along with Anxiety Disorders in 3 studies
Anxiety Disorders: Persistent and disabling ANXIETY.
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"Memantine showed safety in reducing acute symptoms of anxiety and other symptoms encountered in pediatric patients with autism spectrum disorders." | 9.22 | Evaluation of memantine's efficacy and safety in the treatment of children with autism spectrum disorder: A systematic review and meta-analysis. ( Abdelgalil, MS; Ali, MM; Benmelouka, AY; Brimo Alsaman, MZ; Elgendy, AMN; Elnaiem, W; Mogheeth, A; Yousof, SM, 2022) |
"Memantine was well tolerated, and there were no serious adverse effects." | 6.74 | Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial. ( Bystritsky, A; Feusner, JD; Kerwin, L; Saxena, S, 2009) |
"Memantine showed safety in reducing acute symptoms of anxiety and other symptoms encountered in pediatric patients with autism spectrum disorders." | 5.22 | Evaluation of memantine's efficacy and safety in the treatment of children with autism spectrum disorder: A systematic review and meta-analysis. ( Abdelgalil, MS; Ali, MM; Benmelouka, AY; Brimo Alsaman, MZ; Elgendy, AMN; Elnaiem, W; Mogheeth, A; Yousof, SM, 2022) |
"Memantine was well tolerated, and there were no serious adverse effects." | 2.74 | Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial. ( Bystritsky, A; Feusner, JD; Kerwin, L; Saxena, S, 2009) |
Research
Studies (3)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors
Authors | Studies |
---|---|
Elnaiem, W | 1 |
Benmelouka, AY | 1 |
Elgendy, AMN | 1 |
Abdelgalil, MS | 1 |
Brimo Alsaman, MZ | 1 |
Mogheeth, A | 1 |
Ali, MM | 1 |
Yousof, SM | 1 |
Yuanyuan, J | 1 |
Junyan, Z | 1 |
Cuola, D | 1 |
Jingjing, C | 1 |
Yuhui, S | 1 |
Dan, X | 1 |
Wei, D | 1 |
Yongsheng, Z | 1 |
Feusner, JD | 1 |
Kerwin, L | 1 |
Saxena, S | 1 |
Bystritsky, A | 1 |
Clinical Trials (1)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Differential Efficacy of Memantine for Obsessive-compulsive Disorder vs. Generalized Anxiety Disorder: an Open-label Trial[NCT00674219] | Phase 3 | 17 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Psychometric Scores
"Participants in the OCD group were rated using the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), a standard measure of obsessive-compulsive disorder (OCD) severity in pharmacotherapy studies. It is administered by a trained rater. It comprises 10 items assessing OCD symptoms (e.g. time spent, degree of control, severity). Each item is scored on a scale from 0 (not present) to 4 (severe) [total score range = 0-40] over the previous week. The higher the number on the Y-BOCS, the more severe the symptoms.~Participants in the GAD group were rated using the Hamilton Anxiety Rating Scale (HARS), a standard measure of anxiety severity in pharmacotherapy studies. It is administered by a trained rater. It comprises 14 items assessing anxiety symptoms. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe." (NCT00674219)
Timeframe: Baseline, 12 weeks
Intervention | units on a scale (Mean) | |
---|---|---|
12 weeks | Baseline | |
GAD Group | 18.86 | 24.3 |
OCD Group | 16.4 | 27.6 |
Reviews
1 review available for memantine and Anxiety Disorders
Article | Year |
---|---|
Evaluation of memantine's efficacy and safety in the treatment of children with autism spectrum disorder: A systematic review and meta-analysis.
Topics: Anxiety Disorders; Autism Spectrum Disorder; Child; Excitatory Amino Acid Antagonists; Humans; Meman | 2022 |
Trials
1 trial available for memantine and Anxiety Disorders
Article | Year |
---|---|
Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial.
Topics: Adult; Anxiety Disorders; Excitatory Amino Acid Antagonists; Female; Humans; Male; Memantine; Middle | 2009 |
Other Studies
1 other study available for memantine and Anxiety Disorders
Article | Year |
---|---|
Memantine attenuated alcohol withdrawal-induced anxiety-like behaviors through down-regulating NR1-CaMKII-ERK signaling pathway.
Topics: Alcoholism; Animals; Anxiety; Anxiety Disorders; Calcium-Calmodulin-Dependent Protein Kinase Type 2; | 2018 |